Details of the Drug Combinations

General Information of This Drug (ID: DMQ2AIJ)

Drug Name
Lestaurtinib   DMQ2AIJ
Synonyms A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Approved (orphan drug) [1]
Myeloid leukaemia 2B33.1 Phase 3 [1]
Psoriasis vulgaris EA90 Phase 2/3 [1]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

14 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Decitabine + Lestaurtinib DCAP3X1 Decitabine Ewing sarcoma (Cell Line: TC-71) [2]
Efaproxyn + Lestaurtinib DC5M4XU Efaproxyn Ewing sarcoma (Cell Line: TC-71) [2]
Lestaurtinib + Buparlisib DC4BKF1 Buparlisib Ewing sarcoma (Cell Line: TC-71) [2]
Lestaurtinib + Formononetin DC556X0 Formononetin Ewing sarcoma (Cell Line: TC-71) [2]
Lestaurtinib + Mitomycin DC2T0WD Mitomycin Diffuse large B cell lymphoma (Cell Line: TMD8) [2]
Lestaurtinib + Bardoxolone methyl DCMOLMV Bardoxolone methyl Ewing sarcoma (Cell Line: TC-71) [2]
Lestaurtinib + Ispinesib DC3KNKN Ispinesib Ewing sarcoma (Cell Line: TC-71) [2]
LY2874455 + Lestaurtinib DCNAMQ9 LY2874455 Ewing sarcoma (Cell Line: TC-71) [2]
Mitomycin + Lestaurtinib DCX8X8P Mitomycin Ewing sarcoma (Cell Line: TC-71) [2]
Nintedanib + Lestaurtinib DCU9OEW Nintedanib Ewing sarcoma (Cell Line: TC-71) [2]
OSI-027 + Lestaurtinib DC6WBB2 OSI-027 Ewing sarcoma (Cell Line: TC-71) [2]
OSI-906 + Lestaurtinib DCF263I OSI-906 Ewing sarcoma (Cell Line: TC-71) [3]
Panobinostat + Lestaurtinib DC26QPP Panobinostat Ewing sarcoma (Cell Line: TC-71) [2]
SNX-5422 + Lestaurtinib DC9NRM1 SNX-5422 Ewing sarcoma (Cell Line: TC-71) [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 14 DrugCom(s)
2 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Lestaurtinib + Lestaurtinib DCFN3PJ Lestaurtinib Psoriasis [4]
Lestaurtinib + Lestaurtinib DCYWN5X Lestaurtinib Psoriasis [4]
------------------------------------------------------------------------------------

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5672).
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
4 ClinicalTrials.gov (NCT00236119) Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis